Mice lacking granulocyte colony-stimulating factor (G-CSF) were generated by targeted disruption of the G-CSF gene in embryonal stem cells. G-CSF-deficient mice (genotype G-CSF-/-) are viable, fertile, and superficially healthy, but have a chronic neutropenia. Peripheral blood neutrophil levels were 20% to 30% of wild-type mice (genotype G-CSF+/ +) and mice heterozygousfor the null mutation had intermediate neutrophil levels, suggesting a gene-dosage effect. In the marrow of G-CSF-/-mice, granulopoietic precursor cells were reduced by 50% and there were reduced levels of granulocyte, macrophage, and blast progenitor cells. Despite G-CSF deficiency, mature neutrophils were still present in the blood and marrow, indicating that other factors can support neutrophil production in vivo. G-CSF-I-mice had reduced numbers of neutrophils available for rapid mobilization into the circulation by a single dose of G-CSF. G-CSF
RANULOCYTE colony-stimulating factor (G-CSF) is
a glycoprotein that influences the survival, proliferation, differentiation, and function of mature neutrophil granulocytes and their precursors. ' The effects of excess G-CSF in vivo have been studied in murine models by injecting pharmacologic doses of G-CSF2-4 and by reconstituting mice with marrow cells overproducing G-CSF. ' These studies demonstrate that G-CSF is a potent and relatively specific stimulator of neutrophil production in vivo, but they do not define its usual physiologic A number of observations suggest that G-CSF plays an important regulatory role in granulopoiesis in vivo. In humans, low neutrophil levels coexist with high serum G-CSF levels in some clinical sit~ations,~*~ suggesting a regulatory role for G-CSF as part of a homeostatic regulatory loop responsible for "steady-state" neutrophil prod~ction.~ A canine model exists that lends support to this hypothesis. Prolonged administration of human G-CSF to dogs at first induces a neutrophilia, but ultimately results in profound neutropenia, probably due to the development of antihuman-G-CSF antibodies that cross-react with and neutralize endogenously produced canine G-CSF." However, this study does not define the impact of absolute G-CSF deficiency and therefore does not delineate the full extent to which G-CSF contributes to the regulation of neutrophil production. G-CSF may also have a regulatory role as an "emergency" factor,'*7 augmenting granulopoiesis when extra neutrophils are required acutely, such as during infections; the concurrence of elevated numbers of neutrophils and high serum G-CSF levels in some infections supports this notion.'' Collectively, although these data implicate G-CSF in both steady state and emergency neutrophil production, the precise role of G-CSF in vivo remains inferred rather than defined.
One definitive approach to delineate the in vivo role of hematopoietic growth factors is to study mice genetically deficient in various factor^.^." Murine models of factor deficiency have been reported for macrophage colony-stimulat- ing factor (M-CSF; also known as CSF-1)'3"5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) 16 .17 and also of mice deficient in both these factors." Studies of mice deficient in these hematopoietic growth factors have provided definitive insights into the physiologic roles of these factors.
We now report the generation and phenotype of mice lacking G-CSF due to a defined disruption of the G-CSF gene, generated by homologous recombination in embryonal stem cells. The granulopoietic defect characterizing G-CSFdeficient mice indicates that G-CSF plays a major role in steady-state neutrophil production in vivo, and also suggests that G-CSF is necessary for emergency granulopoiesis. (Fig 1A) contained, from 5' to 3', 1.1 kb of the G-CSF promoter region (Asp700-NCO I, the NCO I site spanning the translational initiation ATG); the Escherichia coli lac-z gene with a modified 5' end to facilitate cloning N, NCO I; Sa, Sac I; Sc, Sca I; X, Xba I), probe A (corresponding t o deleted sequences), probe B (external t o construct, diagnostic for targeted disruption), and sites of PCR primer hybridization (a, b. and c; see text). In the disrupted allele, exons 1 and 2, and most of exon 3 are deleted and replaced by the E coli lac-z gene (lac-z), human pglobin 3' untranslated and polyA addition sequences (pg), and a hybrid neomycin phosphotransferase expression cassette (Neo) (for details see text). (B) PCR diagnosis of G-CSF genotype. PCRs containing primers a, b. and c (see A) generate PCR products of 1.4 and 1.3 kb from wild-type (+/+l and homozygous null (-/-l template DNA, and both productsfrom heterozygous template DNA (+/-l. PCR products visualized on ethidium-stained 1.5% agarose gel, with size markers as indicated and negative control reaction containing Tris-EDTA buffer (TE) used as diluent for DNA samples, are shown. IC) Southern blot of Xba l-digested tail DNA from PCR-genotyped G-CSF+/+ and G-CSF-I-mice shown in (B), probed first with probe A (see A), confirming that the exons 1 through 3 are present in wild-type (G-CSF+/+) DNA but absent from G-CSF-/-DNA, and then reprobed without washing with probe B (see A), confirming that the G-CSF-/ -mouse is homozygous for a disrupted G-CSF allele characterized, as predicted, by a 5-kb larger Xba I species.
MATERIALS AND METHODS

G-CSF targeting vector and isolation of targeted embryonal stem (ES) cell clones. The G-CSF targeting vector
quences and polyA addition motif from pMC1Neo'": and approximately 6.3 kb of genomic sequences from the BamHI site in exon 3 of the G-CSF gene to the next BamHI site. The vector backbone was a hybrid derived from pSP73 (bp 1809-6) and pBR322 (bp 2029-3061) ligated at the Asp700 site in the ampR gene. Genomic
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From sequences were derived from 4 overlapping partially mapped Xbacteriophage clones spanning approximately 15 kb encompassing the murine G-CSF gene, isolated by screening a BALB/c liver genomic library in the EMBL-3 SP6/T7 vector (Clontech, Palo Alto, CA) with the murine G-CSF cDNA2' (G.J. Lieschke, unpublished data, May 1990). The targeting vector was constructed to delete bp 5-703 of the G-CSF gene (between NCO I and BarnHI sites, encompassing exons 1, 2, and most of exon 3) : ' The lac-z gene was included as a reporter gene to identify cells in which the G-CSF promoter was active. The targeting vector was linearized with Asp700 before electroporation into 129/0LA-derived E14 ES cells (gift of M.L. Hooper, University of Edinburgh, UK)23 that were maintained and subsequently selected in G418 (Geneticin; GIBCO, Grand Island, NY) as previously de~cribed.'~ After 10 days of G418 selection, individual G418-resistant clones were cloned and replated. DNA from each ES cell colony was screened by a polymerase chain reaction (PCR) diagnostic for integration of a targeting vector by homologous recombination. The FCR primers were (see Fig 1A) (a) 5"TCCATG-ACATCTGTGGCCACCAGA-3', corresponding to sequences 5' of the Asp700 site in the G-CSF promoter (G.J. Lieschke, unpublished data, December 1991); (b) 5'-CGGCCTCTCGTCCTGACCATA-GTG-3', corresponding to sequences in exon 2 of the G-CSF gene deleted by targeted construct integration (bp 152-175 of the genomic G-CSF sequence)u; and (c) 5"CTGCAAGGCGATTAAGTTGG-GTAA-3', corresponding to the 5' region of the E coli lac-z gene. In PCRs, primers a and b generate a 1.4-kb product from wild-type template DNA, and a and c a 1.3-kb product from DNA containing a correctly integrated targeted construct (Fig 1B) . PCRs (20 pL) contained ~2 5 0 ng DNA, 67 mmoVL Tris-HC1 (pH 8.8),16.6 mmoU L (NH&S04, 0.45% Triton X-100, 200 pg/mL gelatin, 2 mmoVL MgCl', 250 pmoVL of each dNTP, 20 to 40 ng of each primer, and 1.5 U of Taq polymerase. After initial denaturation (95°C for 150 seconds), 35 amplification cycles were performed (95°C for 50 seconds, 62°C for 50 seconds, 72°C for 60 seconds). During screening of ES cell clones, F'CRs to identify wild-type and disrupted alleles were performed separately to maximize sensitivity. For screening of DNA prepared from mouse tails, both PCRs were performed together in one reaction (Fig IB) . Southern blot analysis was performed to characterize the structure of the mutant G-CSF allele. Xba I-digested tail DNA was probed with a radiolabeled DNA fragment corresponding to G-CSF genomic sequences deleted from the targeting construct (Fig lA, probe A, sequences between NCO I-BarnHI), and reprobed without washing with probe B (Fig 1A) corresponding to sequences lying outside the targeting construct (the adjacent 0.7-kb Sac I-Sac I and 0.4-kb Sac I-BgZ I1 sequences).
Mice. Two clonally independent E14-derived ES cell lines with a targeted G-CSF gene were injected into C57BL/6 blastocysts, but only chimeras from one clone transmitted the disruptive mutation through the germline in matings with C57BU6 females. G-CSF genotypes were routinely determined by PCR analysis of tail DNA and were designated as follows: wild-type, G-CSF+/+; heterozygous, G-CSF+/-; and homozygous null, G-CSF-I-. G-CSF-Imice were subsequently bred from G-CSF-/-X G-CSF-/-matings. To generate similarly outbred 129/0LA x C57BW6 G-CSF+/ + control mice, G-CSF+/+ mice were bred from first and second generation G-CSF+/+ littermates. Mice were kept in a conventional animal house. Except where stated, experiments used male and female mice of 6 to 8 weeks of age.
Hisrologic analysis. To survey the tissues of G-CSF-I-mice histologically, hematoxylin and eosin-stained sections of tissues (including lung, thymus, lymph node, connective tissue, liver, kidney, pancreas, stomach, small and large intestines, large blood vessels, spleen, reproductive organs, skin, marrow, and bones) were prepared by standard techniques from 3 pairs of G-CSF+/+ and G-CSF-Imice at age 6 to 8 weeks and from 4 pairs at age 17 to 20 weeks and examined by light microscopy.
Organ-conditioned media and BdF3 G-CSF bioassay. Organconditioned media (CM) from thymus, lung, bladder, bone shaft, and spleen were prepared from pairs of age-matched G-CSF+/+ and G-CSF-/-mice, as previously de~cribed?~ and assayed for G-CSF bioactivity in a microwell cellular proliferation assay using Ba/ F3 cellsz6 transfected with a G-CSF receptor cDNA expression vector (designated BalF3-GR). which conferred to BalF3 cells the ability to proliferate in the presence of G-CSF (D. Metcalf, unpublished data, February 1994) . Although Ba/F3 cells respond to interleukin-3 (IL-3). untransfected BaF3 cells showed no proliferative response to the test organ CM from wild-type mice, indicating that neither IL-3 nor any other unknown proliferative stimulus for Ba/F3 cells was present at measurable levels in the test CM (D. Metcalf, unpublished data, February 1994). The sensitivity of the BaF3-GR bioassay for G-CSF was 30 pg/mL G-CSF in test material.
Hematologic analysis. Blood samples were obtained from either cut tail veins or from the retro-orbital venous plexus using EDTAcoated microhematocrit tubes (Clay Adams, Parsippany, NJ). Hemoglobin, total leukocyte, and platelet estimates were performed on a Sysmex-K1000 automated counter (Toa Medical Electronics CO Ltd, Kobe, Japan) using 1:4 dilutions of peripheral blood in 2 mg/mL EDTA in mouse-tonicity phosphate-buffered saline. Manual 100-or 200-cell leukocyte differential counts of peripheral blood spleen and marrow cells were performed on May-GriinwaldlGiemsa-stained smears or cytospin preparations as appropriate. In experiments involving multiple timed samples from individual mice, 50-to 100-pL samples of retro-orbital plexus venous blood were obtained by repeated ipsilateral eye sampling, unless otherwise stated. In some studies, randomly selected mice were also bled from the contralateral previously unsampled eye to verify that observations reflected systemic changes in leukocyte levels rather than just local effects.
Progenitor cells were assayed in semisolid agar cultures of bone marrow, spleen, or peritoneal cells, as previously de~cribed.'~.~~ Colony formation was stimulated by purified recombinant bacterially synthesized growth factors at the following final concentrations: human G-CSF (10 ng/mL), murine GM-CSF (10 ng/mL), murine IL-3 (10 ng/mL), murine M-CSF (CSF-l) (10 ng/mL), rat stem cell factor (100 ng/mL), murine IL-6 (500 ng/mL), and spleen conditioned medium (10%). Colonies were typed on stained whole-plate preparations as previously described.27 G-CSF administrarion to mice. Bacterially synthesized recombinant human G-CSF (Amgen, Thousand Oaks, CA) was administered by daily subcutaneous injection at a dose of 250 ,@kg for up to 4 days. Peripheral blood was obtained before G-CSF administration (study day 0). 3 hours after the first G-CSF dose, 24 hours after the first G-CSF dose (study day l), and 24 hours after four daily G-CSF doses (study day 4). On study days 1 and 4, groups of 3 G-CSF-treated mice were killed and marrow and spleen cell suspensions were prepared. Cell numbers were determined using samples diluted in 3% (voUvol) glacial acetic acid counted in a hemocytometer, and cytospin preparations were made for differential cell counts. Data presented are pooled from two separate experiments.
Experimental infection wirh Listeria monocytogenes. The outbred G-CSF-/-and G-CSF+/+ mice were derived from C57BU 6 and 129 inbred strains, both of which are resistant to infection with L monocytogenes (LD50 intravenously = 2 X IO5 cfu/mouse).28
Twenty-four-hour, actively growing cultures of L monocytogenes (strain EGD) were washed from the surface of horse blood agar (HBA) plates and the suspension standardized turbidometrically using absorbance at 540 nm on a spectrophotometer (Ultrospec 4050 LBK; Biochron, Cambridge, UK). The dose of viable bacteria was confirmed retrospectively by sampling dilutions onto HBA and counting colonies after 24 hours at 37°C. A dose of 5 X lo3 cfu/ mouse was inoculated intravenously via the tail vein on day 0. On days 1 and 5, groups of mice were killed by cervical dislocation, and livers and spleens were removed separately, weighed, and hoFor personal use only. on November 11, 2017. by guest www.bloodjournal.org From mogenized. To determine organ loads of bacteria, IO-fold serial dilutions of organ homogenates were plated on HBA and bacterial colonies were counted after incubation at 37°C for 24 hours. To determine the hematologic response to infection, eye-bleed samples were taken at baseline and on days 1 and 5 for full blood and differential leukocyte counts. Data presented are the pooled results of two separate experiments, each of which used 5 to 8 mice of each genotype per time point. In one experiment, pieces of organs were fixed in buffered formaldehyde for histologic sections, which were processed by standard.techniques and stained by hematoxylin and eosin and Gram stains (number of mice studied histologically: day 1, n = 5 for both genotypes; day 5, G-CSF+/+ n = 8, G-CSF-/-n = 5).
Srutistics. Data are presented as means 2 standard deviation, unless otherwise stated. Organ loads of L rnonocytogenes are expressed as the logarithm of the bacterial count per organ. Comparisons were made using the x' test, two-tailed paired and unpaired Student's t-tests, and the Wilcoxon rank sum test as appropriate. A P value of less than .05 was regarded as significant. Fig 1A was used to disrupt one G-CSF allele in ES cells by homologous recombination. The vector included a 1.1-kb short arm and 6.3-kb long arm of genomic sequences from the G-CSF gene locus separated by the E coli lac-z reporter gene (placed under control of the G-CSF promoter) and a dominant selectable marker conferring G418 resistance to transfected cells. The construct was designed to disrupt the G-CSF gene by deletion of 0.7 kh of G-CSF genomic sequences encompassing most of exons 1 through 3 and by insertion of the nonhomologous lac-z and selectable marker sequences (Fig 1A) . ES cells were transfected by electroporation and individual (3418-resistant clones screened for targeted incorporation of the vector using a PCR-based screening strategy (see Materials and Methods). Southern blot analysis confirmed that the disrupted allele of mutant ES cell clones identified by PCR had the structure predicted from incorporation of the vector by homologous recombination (data not shown). One ES cell clone with a disrupted G-CSF allele generated chimeras after injection into blastocysts that transmitted the mutation through the germline (the allelic status of mice was determined by PCR analysis of tail DNA, Fig 1B) . Interbreeding of heterozygous animals generated litters in which the three genotypes were represented according to a normal Mendelian pattern of inheritance (71: To confirm the structure of the disrupted G-CSF gene in G-CSF-I-mice, Xba I-digested tail DNA from randomly selected PCR-genotyped G-CSF+/+ and G-CSF-/-mice was analyzed by Southern blotting, first using a probe corresponding to the 0.7-kb NCO I-BamHI sequences predicted to be deleted from the disrupted G-CSF gene (Fig lA, probe  A) . As predicted, G-CSF+/+, but not G-CSF-/-, tail DNA contained a 12-kb species hybridizing with this probe (Fig  lC) , confirming that these sequences were deleted from the genome of G-CSF-/-mice. However, G-CSF-/-DNA contained a 5-kb larger Xba I species when hybridized with probe B corresponding to sequences lying in the G-CSF promoter region outside the targeting vector (Fig lA) , confirming that G-CSF-/-mice were homozygous for a mutant G-CSF allele of the predicted structure (Fig IC) .
RESULTS
Generation of mice with a disrupted G-CSF gene. The targeting vector shown in
Ver$cation that organs from homozygous null mice were unable to synthesize G-CSF. To confirm that tissues from G-CSF-/-mice lacked the ability to synthesize G-CSF, 4-day organ CM were made from three sets of G-CSF+/+ and G-CSF-/-mice using thymus, lung, bladder, bone shaft, and spleen tissue fragments incubated in serum-free med i~m . '~ These CM were assayed for bioactive G-CSF in microwell assays using Ba/F3 cells transfected with the G-CSF receptor, which confers on Ba/F3 cells the ability to proliferate in response to G-CSF (data not shown). Although BaP3 cells respond to IL-3, untransfected Ba/F3 cells did not respond to test CM made from G-CSF+/+ mice, indicating that Ba/F3 proliferative stimuli including IL-3 or other factors were not present in test CM made under these conditions. When assayed on B e 3 cells transfected with the G-CSF receptor, all organ CM made from G-CSF+/+ mice contained titratable G-CSF bioactivity, whereas G-CSF bioactivity was totally absent from all G-CSF-/-CM (Fig 2) .
Survival of G-CSF-dejcient mice. G-CSF-/-mice developed normally, appeared healthy and were of comparable weight to their G-CSF+/+ littermates. G-CSF-/-mice were fertile and their litters were of normal size (G-CSF-/ -, 7.2 t 2.5 pups [46 litters]; G-CSF+/+, 7.7 t 3.1 pups [32 litters]). Survival of weaned G-CSF-/-mice was not significantly different to that of G-CSF+/+ mice over an observation period of up to 8 months. A histologic survey of nonhematopoietic organs of 6-to 8-week and 17-to 20-week animals showed no consistent morphologic abnormalities.
Hematologic analysis of G-CSF-deficient mice. The peripheral blood of G-CSF-deficient mice showed no significant difference in hemoglobin or platelet levels, but there was a leukopenia due to a significant selective neutropenia (Table 1) . Neutrophil levels of 3-to 4-week G-CSF-/-mice were approximately 30% of those of wild-type mice. The neutropenia of G-CSF-/-mice was chronic and persisted in the oldest G-CSF-/-mice available for analysis (27 to 29 weeks). Heterozygous (G-CSF+/-) 3-to 4-week mice had neutrophil levels intermediate between those of G-CSF+/+ and G-CSF-/-mice (67% of C-CSF+/+), and a similar trend was seen in a smaller group of 27-to 29-week mice. Although some groups of G-CSF-/-mice had reduced circulating lymphocyte levels, this was not a consistent finding (Table 1) . Monocyte levels in 27-to 29-week G-CSF-/-mice were significantly reduced, with a similar trend evident in younger mice. There were no significant differences in numbers of circulating eosinophils, which were low in mice of all three genotypes.
Hematopoiesis was evaluated in three pairs of 6-to 8-week G-CSF-/-and G-CSF+/+ mice. There was no difference in femoral cellularity (G-CSF+/+, 32.2 % 3.9 X lo6 celldfemur; G-CSF-/-, 35.2 2 2.7 X lo6 cells/femur), but G-CSF-/-marrows were depleted of early (myelocyte and promyelocyte) and late (metamyelocyte and polymorphonuclear forms) neutrophil precursors (these comprised, respectively, 9% t 2% and 28% 2 7% of cells in G-CSF+/+ marrows, but only 4% 2 2% and 15% -C 7% of cells in G- Table 2 ). The frequencies of blast CFCs responsive to stem-cell factor with IL-3 (G-CSF+/+, 12 ? 2; G-CSF-/-, 7 2 3; P < .05) were also reduced in G-CSF-/-mice.
The frequencies of eosinophil, megakaryocyte, and erythroid CFCs were consistently low (<7/25,000 marrow cells) in mice of both genotypes. Because the marrow cellularity of G-CSF+/+ and G-CSF-/-mice was equivalent, these reductions in frequencies of progenitor cells reflected absolute reductions in progenitor cell numbers. The spleens of this group IL-3 (G-CSF+/+, 5 ? 1; G-CSF-/-, 2 5 2; P < .05) and 
Dilution of test material added
of G-CSF-/-mice were significantly smaller than controls, and there was a tendency for the frequency of granulocyte and macrophage CFCs to be reduced, although the low frequencies in control animals made comparison difficult (Table  2 ). There was variation in the size of spleens from both G-CSF+/+ and G-CSF-/-mice, and small spleen size was not an invariable feature of G-CSF-/-mice. There were no differences in the number or type of cells recovered from peritoneal washings from G-CSF-/-mice compared with G-CSF+/+ mice.
To assess the role of G-CSF in the phenomenon of "spontaneous" colony formation in crowded unstimulated cultures of 2 X lo5 G-CSF-/-marrow cells/mL were established. "Spontaneous" colony formation was reduced (G-CSF+/+, 81 2 26 colonies/mL; G-CSF-/-, 20 ? 5 colonies/nL; P < .OS) due to reductions in granulocyte, granulocyte-macrophage, and macrophage colonies by 73%, 83%, and 85%, respectively. lo6 for the genotypes G-CSF+/+ and G-CSF-/-, respectively. The spleen weights for these groups of mice were 134 ? 22 and 68 2 6 mg for the genotypes G-CSF+/+ and G-CSF-/-, respectively ( P < . O I L Cultures were stimulated by granulocyte-macrophage (GM-), granulocyte (G-), macrophage (M-) colony-stimulating factor (CSF), IL-3, stem cell factor (SCF), IL-6, erythropoietin (Epo), spleen conditioned medium (SCM), or combinations of these and colonies typed as granulocyte (G), granulocytemacrophage (GM), or macrophage (M). Eosinophil, megakaryocyte, blast cell, and erythroid colony frequencies were also determined (data not shown; for details, see text).
* P < .05 for comparison of G-CSF-/-and G-CSF+/+.
Neutrophil mobilization in G-CSF-deficient mice. Although G-CSF-deficient mice had a chronic deficiency of circulating neutrophils, it was possible that they possessed an adequate noncirculating store of neutrophils in hematopoietic organs or the marginated neutrophil pool. To assess this possibility, we administered G-CSF to G-CSF-/-mice as a neutrophil-mobilizing factor, and measured the increment in circulating neutrophils 3 hours later as an indicator of the number of neutrophils readily mobilizable into the circulation. The 3-hour time point was chosen because it was late enough for the transient neutropenia immediately after G-CSF administration to have reversed:' but early enough for G-CSF-driven neutrophil production not to have been a significant component of the measured in~rement.~' G-CSF+/+ mice had significantly elevated neutrophil levels 3 hours after G-CSF administration (Fig 3A) . G-CSF-/-mice also had significantly elevated neutrophil levels 3 hours after G-CSF administration compared with their baseline levels, but the 3-hour increment in circulating neutrophil levels in G-CSF-treated G-CSF-/-mice was only 21% of that in G-CSF-treated G-CSF+/+ mice ( P < .05; Fig 3A) , indicating that the absolute number of neutrophils mobilizable by G-CSF was significantly reduced in G-CSF-/-mice. (An experiment controlling for the hematologic effects of the sampling method used in this experiment demonstrated that, although sequential sampling itself had a small effect on neutrophil levels at 3 hours, particularly in G-CSF+/+ mice, these effects were minor compared with the effect of G-CSF, Fig 3A and B) .
"Rescue" of granulopoiesis in G-CSF-deficient mice by G-CSF administration. To determine whether the neutropenia and defect in granulopoiesis characterizing G-CSF-/ -mice could be reversed by G-CSF, daily administration of G-CSF was continued for 4 days and levels of hematologic cells in the peripheral blood, marrow, and spleen were monitored on days 1 and 4.
Twenty-four hours after administration of G-CSF, neutrophil levels in the peripheral blood of G-CSF-/-mice were comparable to those in G-CSF+/+ mice at baseline (Fig  3) . G-CSF administration resulted in reduced marrow and increased splenic cellularity in mice of both genotypes on day 1 (Table 3 ). There was no significant change in the proportion of granulocyte precursor cells in the marrow on day 1 compared with baseline, with G-CSF-/-mice remaining depleted of neutrophil precursor cells (Table 3) . Splenic granulopoiesis had increased in mice of both genotypes, although significantly more in G-CSF+/+ than in G-CSF-/-mice (Table 3) .
After 4 days of G-CSF treatment, blood neutrophil levels in mice of both genotypes were elevated above the baseline for G-CSF+/+ mice (Fig 3) . There was a marked proportional increase in late neutrophil precursor cells in the marrow of mice of both genotypes, but the increase was greater in G-CSF-/-mice and marrow granulopoiesis was proportionally similar in G-CSF+/+ and G-CSF-/-mice (Table  3 ). In the spleen, granulopoiesis was increased in mice of both genotypes, but only in G-CSF-/-mice had it increased to proportionally greater levels than on day 1.
Infection of G-CSF-deficient mice with L monocytogenes. In initial experiments, we confirmed that neutrophilia and monocytosis characterize the hematologic response of wildtype mice to experimental infection with L monocytogene^.^'.^^ We were therefore interested to assess the consequences of L monocytogenes infection in G-CSF-deficient mice as a model of "emergency" granulopoiesis. G-CSF-I -mice were found to have a markedly impaired ability to control L monocytogenes infection and marked impairment of the usual hematopoietic response to this infection. On day 1 (the day after administration of bacteria), the levels of L monocytogenes in the liver and spleen were not different between G-CSF+/+ and G-CSF-/-mice (Fig 4A) . However, by day 5, G-CSF-/-mice had significantly higher levels of L monocytogenes in both these organs, indicating that G-CSF-/-mice had an impaired ability to control the infection (Fig 4A) . The cumulative mortality from infection
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of G-CSF-/-mice by day 5 was 50% (8/16), whereas no deaths occurred in G-CSF+/+ mice over the same period. The G-CSF-/-mice that died had high levels of bacteria (>los cfu/organ). (Similar observations about organ bacterial loads were made when the data were expressed as cfu
The granulopoietic response to L monocytogenes infection was markedly diminished in G-CSF-/-mice despite the stimulus of the ongoing infection. G-CSF+/+ mice develPer gram.) * Study day 0 is pre-treatment; study days 1 and 4 are 24 hours after 1 and 4 daily doses of G-CSF respectively.
t The first value is the number of mice for determination of tissue cellularity, and second value is the number of mice for differential count.
* Marrow cellularity is cells x 107/femur; spleen cellularity is cells x 1O8/spleen. 5 P < .05 for comparison between G-CSF+/+ and G-CSF-I-mice on the same study day.
ll P < .05 for comparison between mice of the same genotype at baseline and on the study day indicated.
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Day after Listeria Infection oped a significant neutrophilia by 1 day after L monocytogenes inoculation, but the l-day neutrophil increment in G-CSF-/-mice was only 15% of that in G-CSF+/+ controls (Fig 4B) . A neutrophilia persisted at day 5 in G-CSF+/+ mice, but, in surviving G-CSF-/-mice, the day-5 neutrophil levels had decreased to levels no different to baseline values (Fig 4B) . Furthermore, among the few circulating neutrophils in surviving G-CSF-/-mice on day 5, there was a high percentage of very immature forms in some mice (promyelocytes and myelocytes comprised 33% 2 42%
[range, 2% to loo%] of circulating neutrophils in G-CSF-/ -mice compared with 5% 2 3% [range, 0% to lo%] in G-CSF+/+ mice, P < .001 by Wilcoxon rank sum test). Mice of both genotypes developed a lymphopenia during this experiment that was more marked in G-CSF-/-mice on days 1 and 5, despite there being no significant difference between groups at baseline (Fig 4C) . A monocytosis developed in mice of both genotypes, but this response was delayed in G-CSF-/-mice. Day 1 and 5 monocyte levels were significantly lower in G-CSF-/-mice than in G-CSF+/+ mice despite there being no difference at baseline, and on day 1, G-CSF+/+ but not G-CSF-/-mice already had elevated monocyte levels (Fig 4C) . On days 1 and 5, mice of both genotypes developed hepatic microabscesses composed predominantly of mononuclear cells. G-CSF-/-mice with the highest bacterial loads had the highest density and largest hepatic microabscess. In the spleens of G-CSF+/+ mice, there was prominent subcapsular granulopoiesis and many mature segmented neutrophils in sinusoidal areas on both day 1 and 5, whereas, in G-CSF-/-spleens, there was markedly less subcapsular granulopoiesis and fewer neutrophils in splenic sinusoids, particularly on day 5. This striking histologic observation was reflected in differential counts of spleen cell suspensions (percentage of granulocytic cells in spleen cell suspensions G-CSF+/+, 12% 2 5% [n = from mice analyzed on day 5 41; G-CSF-/-i 3% 2 l % [n = 31, P < .02).
DISCUSSION
The role of G-CSF in regulating neutrophil production under "steady-state" and "emergency" conditions in vivo has previously been inferred rather than defined. "Steadystate" granulopoiesis refers to the situation of regulated neutrophil production that maintains circulating neutrophil levels in a narrow normal range, a situation envisaged to involve a homeostatic loop with a driving factor (putatively G-CSF) as the granulopoietic stimulus and an as yet undefined negative feedback that may involve the neutrophil itself.33 L 'Emergency" granulopoiesis describes situations in which an acute event such as infection drives neutrophil production above basal levels.'.' In this situation, an emergency factor (again putatively G-CSF) is envisaged to override baseline regulated neutrophil production; this overriding emergency factor is generated as part of the emergency response to the infective insult. Indirect evidence implicating G-CSF in a homeostatic loop controlling steady-state granulopoiesis includes the demonstration of coexistent low neutrophil levels and high levels of endogenously produced G-CSF in some neutropenic clinical states,8 and the description of neutropenia that developed in dogs treated with human G-CSF, apparently resulting from antihuman G-CSF antibodies with cross-reactivity to endogenously produced canine G-CSF." Indirect evidence implicating G-CSF as an emergency granulopoietic factor include its ability to stimulate neutrophil production when administered in pharmacologic doses2-4.29 and the coexistence in some infective states of high neutrophil levels and high serum levels of endogenously produced
The studies we now report provide direct evidence implicating G-CSF as indispensible for steady-state granulo-
G-CSF."
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From poiesis in vivo. The granulopoietic defect characterizing G-CSF-/-mice indicates that G-CSF has a pivotal role in vivo in maintaining normal baseline levels of circulating neutrophils, mobilizable neutrophil reserves, and marrow granulopoiesis. Interestingly, G-CSF-/-mice still have some mature segmented neutrophils, indicating that full neutrophilic differentiation can still proceed under the influence of other factors alone, although these factors cannot fully compensate for G-CSF deficiency because neutrophil production still remains quantitatively impaired. G-CSF-/-mice do not show the arrest of neutrophil development that characterizes many cases of Kostmann's and therefore our data support the view that it is unlikely that G-CSF deficiency underlies this form of human congenital neutropenia.' However, our murine model of congenital chronic neutropenia due to G-CSF deficiency suggests that, among autosomal recessive forms of human congenital neutropenia, a subgroup may be found to have genetically based G-CSF deficiency.
As a model of emergency granulopoiesis, we studied the hematologic response to experimental infection with L monocytogenes. These data indicate that G-CSF is necessary for a normal emergency granulopoietic response in vivo. Although the baseline neutrophil depletion of G-CSF-/-mice may have compromised the capacity for remaining factors to stimulate "emergency" neutrophil production, these data indicate that G-CSF is at least permissive for a normal granulopoietic response to this infection, because in the absence of a G-CSF-driven marrow at the onset of infection, the granulopoietic response to infection is severely impaired. Furthermore, it is interesting that G-CSF itself can stimulate granulopoiesis of G-CSF-/-mice within 4 days to suprabasal levels, whereas the factors that remain in G-CSF-/-mice cannot do so during 5 days of an ongoing Listeria infection, indicating that the factors remaining are not as efficient as stimulating granulopoiesis as pharmacologic doses of G-CSF itself. The opportunity to restore granulopoiesis and neutrophil reserves of G-CSF-/-mice by G-CSF treatment provides for the first time an experimental situation in which the requirement for G-CSF production to drive emergency granulopoiesis can be directly assessed. Future experiments evaluating the role of G-CSF in emergency situations can be designed to start with a neutrophilreplete G-CSF-treated G-CSF-/-animal.
G-CSF-treated G-CSF-/-mice resemble G-CSFtreated G-CSF+/+ mice after 4 days of G-CSF administration at pharmacologic doses, at least in terms of blood neutrophil levels and morphologically recognizable marrow precursors, although G-CSF-driven splenic granulopoiesis after 4 days of G-CSF therapy was still less than that in G-CSF+/ + mice treated with G-CSF for the same duration. This possibly reflected the reduced size of the total progenitor pool of G-CSF-/-mice at the start of G-CSF therapy. These data appear consistent with the kinetics of granulopoiesis during treatment of G-CSF-replete mice with pharmacologic doses of G-CSF. 30 A number of previous observations indicate that the specificity of G-CSF for cells of the neutrophil lineage in vivo is probably not absolute. For example, administration of high doses of G-CSF to mice results in a modest increase in circulating monocyte levels,30 and G-CSF administration mobilizes hematopoietic progenitor cells of all lineages into the circ~lation.~~ Three observations from our studies suggest that effects of G-CSF on monocyte/macrophage lineage cells are indeed of physiologic relevance. G-CSF-/-mice had a deficiency of macrophage progenitor cells. Older G-CSF-/ -mice had reduced numbers of circulating monocytes. In G-CSF-/-mice, the peripheral blood monocyte response to experimental infection with L monocytogenes was delayed. However, it remains possible that the effects of G-CSF on the monocyte/macrophage lineage in vivo are indirect rather than direct. Studies have also demonstrated effects of G-CSF on early progenitor cells, such as stem cell factor-responsive blast progenitor cells." The reduction in numbers of these blast progenitor cells in G-CSF-/-mice indicates that the effects of G-CSF on early progenitor cells are of physiologic relevance. Our data demonstrating a marked impairment of G-CSF-/ -mice to control Listeria infection indirectly support the emerging evidence from studies using animals depleted of neutrophils by antibody-mediated mechanisms that neutrophils are important in the early stage of defences against this agent.31336 However, because there are also perturbations of monocyte/macrophage lineage hematopoiesis in G-CSF-/-mice, the specificity for the neutrophil lineage of the defect of G-CSF-/-mice in Listeria host defences should not be presumed.
It is of interest to contrast the significant granulopoietic defect in G-CSF-deficient mice with the relatively unperturbed hematopoiesis of GM-CSF-deficient mice.I6 This indicates that, under the prevailing conditions in a conventional animal house, G-CSF, and not GM-CSF, is of pivotal importance in regulating the quantitative balance of neutrophil production in vivo.
Finally, mice deficient in multiple hematopoietic factors provide an opportunity to definitively assess the role of various factors in ameliorating the consequences of single factor deficiency." It will now be of particular interest to interbreed G-CSF-and GM-CSF-deficient mice, to assess the role of GM-CSF in compensating for the neutropenia of G-CSFdeficient mice, and to assess the impact of G-CSF deficiency on the pulmonary consequences of GM-CSF deficiency.
